Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies MJ, Bajaj HS, Broholm C, et al. (REDEFINE 2 Study Group) (2025). New England Journal of Medicine.
Summary
A 68-week phase 3a trial (REDEFINE 2) in 12 countries randomising 1,206 adults with type 2 diabetes and a BMI of 27 or more, 3:1, to weekly cagrilintide plus semaglutide or placebo, with lifestyle intervention. Mean body-weight change was about -14% with the combination versus about -3% with placebo, and about three-quarters of the treatment group reached a glycated haemoglobin of 6.5% or lower versus 16% on placebo. Gastrointestinal adverse events were reported by about 73% of the treatment group and 34% of the placebo group, mostly mild or moderate. Funded by Novo Nordisk.